Medical
Life Sciences
Information Communication
Environment
Nanotechnology / Materials
Energy
Manufacturing Technology
Social Infrastructure
Frontier
Development of a novel therapeutic drug, TMS-007, for acute cerebral infarction
update：2020/06/16
- Features and Uniqueness
-
- The currently approved fibrynolytic therapy is only alteplase, but the use of it has been limited to 5% of patients with acute cerebral infarction due to possible side effects including hemorrhagic infarction that may be life-threatening. TMS-007 is a novel drug that has both fibrynolytic activity and brain protective effects. The aim of this project is to perform a clinical trial of this drug and to further achieve a commercial-based clinical use. We believe that this drug would contribute significantly in the treatment of acute cerebral infarction.
- Keywords
